Goswami R, Tandon R K, Dudha A, Kochupillai N
Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi.
Am J Gastroenterol. 1998 Jul;93(7):1122-5. doi: 10.1111/j.1572-0241.1998.341_u.x.
The aim of this study was to determine the prevalence of steatorrhea in patients with Graves' disease and to assess its significance and correlation with changes in body mass index (BMI), coefficient of fat absorption (COFA), and pancreatic exocrine function in these patients.
Daily dietary fat intake, 24 h fecal fat, COFA, fecal chymotrypsin activity (as an index of pancreatic exocrine function), and total T3, T4, and TSH levels were assessed in 28 patients with active Graves' disease. In 24 patients, reassessment was done after attaining a euthyroid state with carbimazole therapy.
In the thyrotoxic state, 13 of 28 patients had steatorrhea, whereas 15 had normal (<6 g/day) fat excretion (11.4 +/- 6.7 g vs 2.9 +/- 0.8 g, p = 0.0007). Daily fat intake, basal BMI, and serum T3 and T4 levels were similar in the steatorrheic and nonsteatorrheic groups. The mean COFA of the steatorrheic group was significantly lower than that of nonsteatorrheic group (91.6% +/- 4.8% vs 97.7% +/- 0.9%, respectively; p = 0.0006). In the steatorrheic group, fat excretion and COFA normalized after attainment of euthyroidism (changes in fat excretion and COFA = 7.3% +/- 6.3 g/day and 7.7% +/- 5.4%, respectively). Fecal chymotrypsin levels were similar in the steatorrheic and nonsteatorrheic thyrotoxics and in 16 healthy control subjects. The levels did not show any significant changes following attainment of euthyroid status.
Steatorrhea associated with a decrease in COFA can occur in a reversible manner in 46% of patients with Graves' disease. However, steatorrhea in these patients is not linked with weight loss or with pancreatic exocrine dysfunction.
本研究旨在确定格雷夫斯病患者脂肪泻的患病率,并评估其意义以及与这些患者体重指数(BMI)、脂肪吸收系数(COFA)和胰腺外分泌功能变化的相关性。
对28例活动性格雷夫斯病患者评估每日膳食脂肪摄入量、24小时粪便脂肪、COFA、粪便糜蛋白酶活性(作为胰腺外分泌功能指标)以及总T3、T4和TSH水平。对24例患者,在通过卡比马唑治疗达到甲状腺功能正常状态后进行重新评估。
在甲状腺毒症状态下,28例患者中有13例出现脂肪泻,而15例脂肪排泄正常(<6克/天)(11.4±6.7克对2.9±0.8克,p = 0.0007)。脂肪泻组和非脂肪泻组的每日脂肪摄入量、基础BMI以及血清T3和T4水平相似。脂肪泻组的平均COFA显著低于非脂肪泻组(分别为91.6%±4.8%对97.7%±0.9%;p = 0.0006)。在脂肪泻组中,达到甲状腺功能正常后脂肪排泄和COFA恢复正常(脂肪排泄和COFA的变化分别为7.3%±6.3克/天和7.7%±5.4%)。脂肪泻的甲状腺毒症患者和非脂肪泻的甲状腺毒症患者以及16名健康对照者的粪便糜蛋白酶水平相似。达到甲状腺功能正常状态后,这些水平未显示任何显著变化。
46%的格雷夫斯病患者可出现与COFA降低相关的脂肪泻,且呈可逆性。然而,这些患者的脂肪泻与体重减轻或胰腺外分泌功能障碍无关。